Transversal sero-epidemiological study of Bordetella pertussis in Tehran, Iran.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 20 03 2020
accepted: 15 08 2020
entrez: 2 9 2020
pubmed: 2 9 2020
medline: 27 10 2020
Statut: epublish

Résumé

Pertussis remains endemic despite high vaccine coverage in infants and toddlers. Pertussis vaccines confer protection but immunity wanes overtime and boosters are needed in a lifetime. Iran, eligible for the Expanded Program on Immunization that includes the primary immunization, implemented two additional booster doses using a whole-cell vaccine (wPV) at 18 months-old and about 6 years-old. Duration of protection induced by the wPVs currently in use and their impact as pre-school booster are not well documented. This study aimed at assessing vaccination compliance and at estimating the duration of protection conferred by vaccination with wPV in children aged < 15 years in Tehran, Iran. Detailed information on vaccination history and capillary blood samples were obtained from 1047 children aged 3-15 years who completed the 3 doses-primary pertussis immunization, in Tehran. Anti-pertussis toxin IgG levels were quantified by ELISA. Compliance was very high with 93.3% of children who received the three primary and 1st booster doses in a timely manner. Timeliness of the 2nd booster was lower (63.3%). Rate of seropositive samples continuously and significantly increased from 1-2 to 5-6 years after 1st booster attaining 30.4% of children exhibiting serological sign of recent contact with B. pertussis. Second booster dating back 1 or 2 years was associated with high antibody titers, which significantly decreased within 3 years from injection. Among children who received 2nd booster injection more than 2 years before serum analysis, seroprevalence of pertussis infection was 8.4% and seropositivity rate was higher from the 10 years-old group. Seropositivity in children aged 6-7 years with no 2nd booster supports the need for a vaccination at that age. Adolescent booster may also be considered.

Identifiants

pubmed: 32870922
doi: 10.1371/journal.pone.0238398
pii: PONE-D-20-08084
pmc: PMC7462262
doi:

Substances chimiques

Antibodies, Bacterial 0
Immunoglobulin G 0
Pertussis Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0238398

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pathog Dis. 2015 Oct;73(7):
pubmed: 26208655
East Mediterr Health J. 2014 Oct 20;20(10):623-6
pubmed: 25356693
J Pediatr. 1998 Jun;132(6):983-8
pubmed: 9627590
Vaccine. 2013 Aug 12;31(36):3732-8
pubmed: 23742995
Wkly Epidemiol Rec. 2015 Aug 28;90(35):433-58
pubmed: 26320265
Roum Arch Microbiol Immunol. 2013 Oct-Dec;72(4):250-4
pubmed: 24923108
Lancet Infect Dis. 2011 Jul;11(7):557-70
pubmed: 21600850
Iran J Public Health. 2012;41(10):65-71
pubmed: 23304664
Vaccine. 2016 May 23;34(24):2635-43
pubmed: 27109562
Lancet Infect Dis. 2017 Sep;17(9):974-980
pubmed: 28623146
Clin Diagn Lab Immunol. 1996 Jan;3(1):93-7
pubmed: 8770511
Vaccine. 2018 Dec 18;36(52):7936-7942
pubmed: 30448334
J Clin Microbiol. 2010 Dec;48(12):4459-63
pubmed: 20943873
Jundishapur J Microbiol. 2014 Nov;7(11):e12421
pubmed: 25774274
Emerg Infect Dis. 2008 Jul;14(7):1159-61
pubmed: 18598649
Eur J Clin Microbiol Infect Dis. 2011 Mar;30(3):307-12
pubmed: 21069406
Hum Vaccin Immunother. 2013 Jan;9(1):112-4
pubmed: 23442584
Lancet Infect Dis. 2017 Sep;17(9):889-890
pubmed: 28623145
J Med Microbiol. 2018 Oct;67(10):1426-1456
pubmed: 30222536
Vaccine. 2017 Oct 27;35(45):6083-6088
pubmed: 28974408
Pediatr Infect Dis J. 2015 Apr;34(4):333-8
pubmed: 25764094
N Engl J Med. 1996 Feb 8;334(6):349-55
pubmed: 8538705
J Infect Dis. 2014 Apr 1;209 Suppl 1:S10-5
pubmed: 24158958
Vaccine. 2003 May 16;21(17-18):2003-14
pubmed: 12706690
BMC Med. 2015 Jun 24;13:146
pubmed: 26103968
Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1893-1900
pubmed: 30094521
J Res Health Sci. 2015 Winter;15(1):54-8
pubmed: 25821027
J Clin Microbiol. 2000 Feb;38(2):800-6
pubmed: 10655388
PLoS One. 2018 Nov 28;13(11):e0207209
pubmed: 30485291
Epidemiol Infect. 2005 Feb;133(1):159-71
pubmed: 15724723
Vaccine. 1998 Dec;16(20):1907-16
pubmed: 9796042
Adv Exp Med Biol. 2019;1183:137-149
pubmed: 31342458
Eur J Clin Microbiol Infect Dis. 1999 May;18(5):341-5
pubmed: 10421041
Iran J Pediatr. 2016 Jun 12;26(4):e5514
pubmed: 27729960

Auteurs

Gaelle Noel (G)

Institut Pasteur, Center for Translational Research, Paris, France.

Farzad Badmasti (F)

Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.

Vajihe S Nikbin (VS)

Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.

Seyed M Zahraei (SM)

Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran.

Yoann Madec (Y)

Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.

David Tavel (D)

Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.

Mohand Aït-Ahmed (M)

Institut Pasteur, Centre for Translational Science, Clinical Coordination, Paris, France.

Nicole Guiso (N)

Institut Pasteur, Center for Translational Research, Paris, France.

Fereshteh Shahcheraghi (F)

Department of Bacteriology, Pertussis Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.

Fabien Taieb (F)

Institut Pasteur, Center for Translational Research, Paris, France.
Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH